Megabios Corporation

University of California

Dnarx

Comfort Care for Animals LLC

Plumb Pharmaceuticals, Inc.

Timothy D Heath

Igor Solodin

Demetrios P Papahadjopoulos

Lisa Ann Krugner-Higby

Chakkrapong Handumrongkul

Amy Lautenbach

Robert James Debs

Jinkang Wang

Yi-Lin Zhang

Pang Shek

Walter H Stern

Provided herein is technology relating to incorporation of drugs into liposomes and particularly, but not exclusively, to methods for incorporating drugs into liposomes using a weak base and related compositions.

Liposome loading

The present invention provides compositions, systems, kits, and methods for expression of one or more biomolecules in a subject, human or non-human mammal, (e.g., at therapeutic levels for the extended periods of time required to produce therapeutic effects). In certain embodiments, compositions, systems, kits, and methods are provided that comprise a first composition comprising polycationic structures (e.g., empty cationic liposomes, cationic micelles, cationic emulsions, or cationic polymers) and a second composition comprising expression vectors (e.g., non-viral expression vectors not associated with liposomes or other carriers) encoding one or more biomolecules of interest.

Systems and methods for nucleic acid expression in vivo

The present invention provides compositions, systems, kits, and methods for generating expression of one or more proteins and/or biologically active nucleic acid molecules in a subject (e.g., at therapeutic levels for extended periods required to produce therapeutic effects). In certain embodiments, systems and kits are provided that comprise a first composition comprising a first amount of polycationic structures, and a second composition comprising a therapeutically effective amount of expression vectors (e.g., non-viral expression vectors not associated with liposomes) that are CpG-free or CpG-reduced, where the expression vectors comprise a first nucleic acid sequence encoding: i) a first therapeutic protein or proteins, and/or ii) a first biologically active nucleic acid molecule or molecules.

Cationic derivatives of biguanide are provided, which are useful in the preparation of lipid carriers for mediating transfection of mammalian cells in vivo and in vitro.

Amphiphilic biguanide derivatives

Cationic amphiphiles are provided that are alkyl or alkoxyalkyl O-phosphate esters of diacylphosphatidyl zwitterionic compounds such as phosphatidylcholine or phosphatidyl ethanolamine. The amphiphiles can be used as carriers for delivering macromolecules intracellularly.

Cationic amphiphiles

Novel, heterocyclic cationic amphiphile and compounds thereof are prepared that are degraded in vivo. Liposomes are produced from the cations that are used as carriers for delivering macromolecules intracellularly and may be targeted to a specific cell type.

Amphiphilic derivatives of piperazine

Amphiphiles containing an imidazdinium ring system are provided that are non-toxic to the host mammal. The amphiphiles are used to produce liposomes useful as carriers for delivering macromolecules intracellularly.

Amphiphilic imidazolinium derivatives

Amphiphilic nitrogen containing imidazolinium derivative compounds and

Catonic amphiphiles

A number of naturally occurring antibodies to human erythrocyte surface antigens are capable of combining with their specific antigens (for example, Rhesus factor), but are not capable of producing visible hemagglutination. Also, the sensitivity of many diagnostic methods, such as in human blood typing, depends upon cell agglutination. The present invention provides liposome-protein conjugates, especially useful for hemagglutination assays, having an enhanced agglutination capacity with respect to antibody from which the conjugates are derived.

Cell agglutination reagent comprising conjugates of antibody covalently

Drugs encapsulated in liposomes are provided, where the drugs are low molecular weight, negatively charged polar drugs and the liposomes are comprised of high transition temperature phospholipids and cholesterol. Relatively large liposomes are employed to enhance drug effectiveness with viable cells.

Growing community of inventors

Madison, WI, United States of America

Timothy D Heath